Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (GB:0HOJ)
LSE:0HOJ
Blueprint Medicines (0HOJ) Share Price & Analysis
0 Followers
0HOJ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$44.18 - $100.99
Previous Close$94.3
Volume162.00
Average Volume (3M)337.00
Market Cap
$5.65B
Enterprise Value$5.71B
Total Cash (Recent Filing)$710.64M
Total Debt (Recent Filing)$774.12M
Price to Earnings (P/E)N/A
Beta0.71
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding61,232,297
10 Day Avg. Volume12
30 Day Avg. Volume337
Standard Deviation0.14
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)42.54
Price to Sales (P/S)82.32
Price to Cash Flow (P/CF)-17.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue24.67
Enterprise Value/Gross Profit23.73
Enterprise Value/Ebitda-12.10
Forecast
1Y Price Target
$98.33Price Target Upside4.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Blueprint Medicines News
PremiumCompany Announcements
Blueprint Medicines Divests GAVRETO Rights to Rigel
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe upcoming Investigational New Drug application for BLU-808 and potential Phase 1 clinical trial demonstrate Blueprint's advancing expertise in mast cell biology and its commitment to addressing unmet medical needs.
Drug DevelopmentBlueprint Medicines Corporation's BLU-808 exhibits exceptional selectivity and potential for chronic urticaria, positioning it as a promising candidate in mast cell disorder treatments.
Financial PerformanceAnalyst reiterates a Buy rating on BPMC with a Market Outperform rating and a price target of $114, reflecting confidence in the company's revenue growth and stock potential.
Bears Say
Competitive ThreatCompetitive landscape shows other companies also developing mast cell-driven disease therapies, posing potential challenges to Blueprint's market position.
Financial PerformanceGavreto US sales have been disappointing (<$30mn annually).
Market ExpectationAnalysts expect Ayvakit peak sales will fall short of Blueprint’s $2 billion projection.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.52% Other Institutional Investors
99.48% Public Companies and
Individual Investors
0HOJ FAQ
What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest share price was $44.18 and its highest was $100.99 in the past 12 months.
What is Blueprint Medicines’s market cap?
Currently, no data Available
When is Blueprint Medicines’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Blueprint Medicines’s earnings last quarter?
Currently, no data Available
Is Blueprint Medicines overvalued?
According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
Does Blueprint Medicines pay dividends?
Blueprint Medicines does not currently pay dividends.
What is Blueprint Medicines’s EPS estimate?
Blueprint Medicines’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Blueprint Medicines have?
Currently, no data Available
What happened to Blueprint Medicines’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Blueprint Medicines?
Among the largest hedge funds holding Blueprint Medicines’s share is Woodline Partners LP. It holds Blueprint Medicines’s shares valued at 75M.
---
Blueprint Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$98.33 (4.42% Upside)
$98.33 (4.42% Upside)
Blogger Sentiment
Bullish
GB:0HOJ Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.71%
12-Months-Change
Fundamentals
Return on Equity
-157.13%
Trailing 12-Months
Asset Growth
-22.27%
Trailing 12-Months
Company Description
Blueprint Medicines
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
---
0HOJ Stock 12 Months Forecast
Average Price Target
$98.33
▲(4.42% Upside)
Technical Analysis
Best Analysts Covering 0HOJ
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+14.22%
reiterated a buy rating 4 months ago
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +14.22% per trade.
---